Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Karin Knobe

Karin Knobe

Global Head of Development, Rare Diseases at Sanofi

Appears in 1 story

Notable Quotes

"These recognitions highlight the critical unmet need that persists for people living with wAIHA." — February 2026 press release

Stories

First BTK inhibitor advances toward approval for warm autoimmune hemolytic anemia

New Capabilities

Leading rilzabrutinib development program

For 50,000 Americans with warm autoimmune hemolytic anemia, there's never been a disease-specific treatment. On February 9, 2026, the FDA granted breakthrough therapy designation to rilzabrutinib—the first BTK inhibitor to reach this milestone for the condition—signaling it may offer substantial improvement over existing therapies.

Updated May 27